Recent advances in the generation of ptp inhibitors and positive outcomes in clinical trials of PTPN1 (protein tyrosine phosphatase, non-receptor type 1; formerly PTP1B) antisense for treatment of type 2 diabetes may soon lead to the use of ptps as markers and novel targets in oncology. The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.